The direct role of CFTR in pancreatic β-cell function has been suggested, given that Ivacaftor increases early-phase insulin secretion and enhances glucagon suppression (38, 39), which may slow CFRD progression. This evidence concerns the gene INS and cystic fibrosis-related diabetes.